Clinical Trial

HALO Clarity™ Cranial Alternating Current Stimulation Therapy for Adults With Moderate-to-Severe Insomnia

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
A prospective, decentralized, individually-randomized, triple-blind\* sham-controlled, superiority trial to evaluate the safety and efficacy of HALO Clarity™ device in reducing insomnia severity. Participants will be randomized to Active and Sham device arms for four (4) weeks. After 4 weeks of treatment, all participants will be followed for an additional 4 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-15.
Trial Details
NCT Number NCT07659366
Lead Sponsor Nexalin Technology
Collaborators: Lindus Health
Conditions Moderate to Severe Insomnia
Enrollment 160 participants
Start Date 2026-06-22
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-10-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-23